|
MechanismDGAT1 inhibitors |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
The clinical evaluation of the effectiveness and research on the mechanism of action of La Roche-Posay Duo+ M emulsion in treating mild to moderate acne
Start Date20 Sep 2024 |
Sponsor / Collaborator- |
[Translation] Study on the bioequivalence of doxycycline hydrochloride tablets in healthy volunteers
以中国健康受试者为试验对象,采用自身交叉对照的试验设计,测定德全药品(江苏)股份有限公司持证生产的盐酸多西环素片给药后血浆中的多西环素在健康受试者体内的血药浓度经时过程,估算相应的药代动力学参数,并以PfizerJapanInc.持证生产的盐酸多西环素片[商品名:Vibramycin,规格:100mg(按C22H24NO8计)]为参比,评价制剂间的生物等效性,并观察盐酸多西环素片在中国健康受试者中的安全性。
[Translation] Healthy Chinese subjects were used as test subjects. A self-crossover design was used to determine the time course of doxycycline concentration in plasma after administration of doxycycline hydrochloride tablets produced by Dequan Pharmaceutical (Jiangsu) Co., Ltd., and to estimate the corresponding pharmacokinetic parameters. Doxycycline hydrochloride tablets produced by Pfizer Japan Inc. under a license [trade name: Vibramycin, specification: 100 mg (calculated as C22H24NO8)] were used as reference to evaluate the bioequivalence between the preparations and to observe the safety of doxycycline hydrochloride tablets in healthy Chinese subjects.
Comparison of the efficacy of spironolactone 5% solution with clindamycin 2% solution in patients with mild to moderate acne vulgaris
100 Clinical Results associated with Moderate to severe acne
100 Translational Medicine associated with Moderate to severe acne
0 Patents (Medical) associated with Moderate to severe acne